Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
07
10
2021
accepted:
17
02
2022
revised:
02
02
2022
pubmed:
11
3
2022
medline:
5
8
2022
entrez:
10
3
2022
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide. Despite recent improvements in treatment and prevention, most of the current therapeutic options are weighted by side effects impacting patients' quality of life. Better patient selection towards systemic treatments represents an unmet clinical need. The recent multidisciplinary and molecular advancements in the treatment of CRC patients demand the identification of efficient biomarkers allowing to personalise patient care. Currently, core tumour biopsy specimens represent the gold-standard biological tissue to identify such biomarkers. However, technical feasibility, tumour heterogeneity and cancer evolution are major limitations of this single-snapshot approach. Genotyping circulating tumour DNA (ctDNA) has been addressed as potentially overcoming such limitations. Indeed, ctDNA has been retrospectively demonstrated capable of identifying minimal residual disease post-surgery and post-adjuvant treatment, as well as spotting druggable molecular alterations for tailoring treatments in metastatic disease. In this review, we summarise the available evidence on ctDNA applicability in CRC. Then, we review ongoing clinical trials assessing how liquid biopsy can be used interventionally to guide therapeutic choice in localised, locally advanced and metastatic CRC. Finally, we discuss how its widespread could transform CRC patients' management, dissecting its limitations while suggesting improvement strategies.
Identifiants
pubmed: 35264786
doi: 10.1038/s41416-022-01769-8
pii: 10.1038/s41416-022-01769-8
pmc: PMC9346106
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
394-407Informations de copyright
© 2022. The Author(s).
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
pubmed: 33433946
doi: 10.3322/caac.21654
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R-H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29:44–70.
pubmed: 29155929
doi: 10.1093/annonc/mdx738
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:329–59.
pubmed: 33724754
doi: 10.6004/jnccn.2021.0012
Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30:viii5–15.
pubmed: 32223939
pmcid: 6859819
doi: 10.1093/annonc/mdz383
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65.
pubmed: 32919526
doi: 10.1016/S1470-2045(20)30445-9
Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291–305.
pubmed: 32702383
doi: 10.1016/j.annonc.2020.06.022
Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86.
pubmed: 24449238
pmcid: 4820760
doi: 10.1200/JCO.2012.45.2011
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:827.
pubmed: 26151329
doi: 10.1038/nm0715-827b
Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016;6:147–53.
pubmed: 26644315
doi: 10.1158/2159-8290.CD-15-1283
Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol. 2018;29:119–26.
pubmed: 28945848
doi: 10.1093/annonc/mdx504
Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25:1415–21.
pubmed: 31501609
pmcid: 6741444
doi: 10.1038/s41591-019-0561-9
Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, et al. Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: circulating tumor cells vs circulating tumor DNA. Target Oncol. 2021;16:309–24.
pubmed: 33738696
pmcid: 8105246
doi: 10.1007/s11523-021-00795-5
Nagayama S, Low S-K, Kiyotani K, Nakamura Y. Precision medicine for colorectal cancer with liquid biopsy and immunotherapy. Cancers (Basel). 2021;13:4803.
doi: 10.3390/cancers13194803
Mazouji O, Ouhajjou A, Incitti R, Mansour H. Updates on clinical use of liquid biopsy in colorectal cancer screening, diagnosis, follow-up, and treatment guidance. Front Cell Dev Biol. 2021;9:660924.
pubmed: 34150757
pmcid: 8213391
doi: 10.3389/fcell.2021.660924
Heidrich I, Abdalla TSA, Reeh M, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as a liquid biopsy marker in colorectal cancer. Cancers (Basel). 2021;13:4500.
doi: 10.3390/cancers13184500
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48.
pubmed: 28252003
doi: 10.1038/nrclinonc.2017.14
Crisafulli G, Mussolin B, Cassingena A, Montone M, Bartolini A, Barault L, et al. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open. 2019;4:e000572.
Jiang J, Gao J, Wang G, Lv J, Chen W, Ben J, et al. Case Report: Vemurafenib treatment in brain metastases of BRAFS365L -mutant lung papillary cancer by genetic sequencing of cerebrospinal fluid circulating tumor DNA detection. Front Oncol. 2021;11:688200.
pubmed: 34178685
pmcid: 8226071
doi: 10.3389/fonc.2021.688200
Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, et al. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol. 2021;18:506–25.
pubmed: 33864051
doi: 10.1038/s41571-021-00495-z
Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27:5586–94.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
pubmed: 24553385
pmcid: 4017867
doi: 10.1126/scitranslmed.3007094
Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26:1859–64.
pubmed: 33020649
doi: 10.1038/s41591-020-1063-5
Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell. 2018;34:148–62.
pubmed: 29990497
doi: 10.1016/j.ccell.2018.06.004
Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3:551–9.
pubmed: 16791214
doi: 10.1038/nmeth898
Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R, Lozano MD, Zubiri L, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61:297–304.
pubmed: 25411185
doi: 10.1373/clinchem.2014.230235
Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71–88.
pubmed: 30410101
doi: 10.1038/s41576-018-0071-5
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745–59.
pubmed: 33506766
doi: 10.1016/j.annonc.2020.02.011
Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578:102–11.
pubmed: 32025015
pmcid: 7054214
doi: 10.1038/s41586-020-1965-x
Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385–9.
pubmed: 31142840
pmcid: 6774252
doi: 10.1038/s41586-019-1272-6
Sidransky D. Nucleic acid-based methods for the detection of cancer. Science. 1997;278:1054–9.
pubmed: 9353179
doi: 10.1126/science.278.5340.1054
Vymetalkova V, Cervena K, Bartu L, Vodicka P. Circulating cell-free DNA and colorectal cancer: a systematic review. Int J Mol Sci. 2018;19:E3356.
pubmed: 30373199
doi: 10.3390/ijms19113356
Issa IA, Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroenterol. 2017;23:5086–96.
pubmed: 28811705
pmcid: 5537177
doi: 10.3748/wjg.v23.i28.5086
Kanth P, Inadomi JM. Screening and prevention of colorectal cancer. BMJ. 2021;374:n1855.
pubmed: 34526356
doi: 10.1136/bmj.n1855
Fleshner P, Braunstein GD, Ovsepyan G, Tonozzi TR, Kammesheidt A. Tumor-associated DNA mutation detection in individuals undergoing colonoscopy. Cancer Med. 2018;7:167–74.
pubmed: 29125240
doi: 10.1002/cam4.1249
Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24:4437–43.
pubmed: 29567812
doi: 10.1158/1078-0432.CCR-18-0143
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17:757–70.
pubmed: 32632268
pmcid: 7790747
doi: 10.1038/s41571-020-0392-0
Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–30.
pubmed: 29348365
pmcid: 6080308
doi: 10.1126/science.aar3247
Killock D. Diagnosis: CancerSEEK and destroy - a blood test for early cancer detection. Nat Rev Clin Oncol. 2018;15:133.
pubmed: 29405203
doi: 10.1038/nrclinonc.2018.21
Petit J, Carroll G, Gould T, Pockney P, Dun M, Scott RJ. Cell-free DNA as a diagnostic blood-based biomarker for colorectal cancer: a systematic review. J Surg Res. 2019;236:184–97.
pubmed: 30694754
doi: 10.1016/j.jss.2018.11.029
Ferrari A, Neefs I, Hoeck S, Peeters M, Van Hal G. Towards novel non-invasive colorectal cancer screening methods: a comprehensive review. Cancers (Basel). 2021;13:1820.
doi: 10.3390/cancers13081820
Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111–30.
pubmed: 31900466
pmcid: 7228650
doi: 10.1038/s41575-019-0230-y
deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55:1337–46.
pubmed: 19406918
doi: 10.1373/clinchem.2008.115808
Johnson DA, Barclay RL, Mergener K, Weiss G, König T, Beck J, et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS ONE. 2014;9:e98238.
pubmed: 24901436
pmcid: 4046970
doi: 10.1371/journal.pone.0098238
Liles EG, Coronado GD, Perrin N, Harte AH, Nungesser R, Quigley N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Commun. 2017;10:27–31.
doi: 10.1016/j.ctarc.2016.12.004
Ned RM, Melillo S, Marrone M. Fecal DNA testing for Colorectal Cancer Screening: the ColoSure
pubmed: 21487548
pmcid: 3050633
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745–59.
pubmed: 33506766
doi: 10.1016/j.annonc.2020.02.011
Lee J, Kim HC, Kim ST, He Y, Sample P, Nakamura Y, et al. Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC). 2021. https://meetinglibrary.asco.org/record/196511/abstract
Victoria M Raymond LH, Guardant Health I, Guardant Health RC. Evaluation of the ctDNA LUNAR-2 Test In an Average Patient Screening Episode (ECLIPSE). 2021. https://meetinglibrary.asco.org/record/194200/abstract
Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256:102–5.
pubmed: 1566048
doi: 10.1126/science.1566048
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–97.
pubmed: 24645800
doi: 10.1056/NEJMoa1311194
Niedermaier T, Balavarca Y, Brenner H. Stage-specific sensitivity of fecal immunochemical tests for detecting colorectal cancer: systematic review and meta-analysis. Am J Gastroenterol. 2020;115:56–69.
pubmed: 31850933
pmcid: 6946106
doi: 10.14309/ajg.0000000000000465
Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, et al. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;30:1580–90.
pubmed: 31373349
doi: 10.1093/annonc/mdz227
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.
pubmed: 18670422
doi: 10.1038/nm.1789
Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016;65:625–34.
pubmed: 25654990
doi: 10.1136/gutjnl-2014-308859
Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5:1124–31.
pubmed: 31070691
pmcid: 6512280
doi: 10.1001/jamaoncol.2019.0528
Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92.
pubmed: 27384348
pmcid: 5346159
doi: 10.1126/scitranslmed.aaf6219
Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5:1710–7.
pubmed: 31621801
pmcid: 6802034
doi: 10.1001/jamaoncol.2019.3616
Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study. PLoS Med. 2021;18:e1003620.
pubmed: 33939694
pmcid: 8128260
doi: 10.1371/journal.pmed.1003620
Taieb J, Taly V, Vernerey D, Bourreau C, Bennouna J, Faroux R, et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration. Ann Oncol. 2019;30:v867.
doi: 10.1093/annonc/mdz394.019
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.
pubmed: 15175436
doi: 10.1056/NEJMoa032709
Kotaka M, Shirasu H, Watanabe J, Yamazaki K, Hirata K, Akazawa N, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol. 2022;40:9. https://meetinglibrary.asco.org/record/204528/abstract .
To YH, Degeling K, Kosmider S, Wong R, Lee M, Dunn C, et al. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics. 2021;39:953–64.
pubmed: 34089503
doi: 10.1007/s40273-021-01047-0
Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225–39.
pubmed: 22962059
pmcid: 3481888
doi: 10.1634/theoncologist.2012-0121
Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, et al. CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112:2915–20.
pubmed: 33931919
pmcid: 8253296
doi: 10.1111/cas.14926
Schraa SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcón C, Phallen J, Sausen M, et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer. 2020;20:790.
pubmed: 32819390
pmcid: 7441668
doi: 10.1186/s12885-020-07252-y
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv263.
pubmed: 29741565
doi: 10.1093/annonc/mdy161
Taylor FGM, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32:34–43.
pubmed: 24276776
doi: 10.1200/JCO.2012.45.3258
Bhoday J, Balyasnikova S, Wale A, Brown G. How should imaging direct/orient management of rectal cancer? Clin Colon Rectal Surg. 2017;30:297–312.
pubmed: 29184465
pmcid: 5703668
doi: 10.1055/s-0037-1606107
Papaccio F, Roselló S, Huerta M, Gambardella V, Tarazona N, Fleitas T, et al. Neoadjuvant chemotherapy in locally advanced rectal cancer. Cancers. 2020;12:3611.
pmcid: 7761666
doi: 10.3390/cancers12123611
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM-K, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42.
pubmed: 33301740
doi: 10.1016/S1470-2045(20)30555-6
Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali AM, et al. Total neoadjuvant therapy for rectal cancer: making sense of the results from the RAPIDO and PRODIGE 23 trials. Cancer Treat Rev. 2021;96:102177.
pubmed: 33798955
doi: 10.1016/j.ctrv.2021.102177
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662–80.
pubmed: 32753728
doi: 10.1038/s41568-020-0285-7
Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2019;68:663–71.
pubmed: 29420226
doi: 10.1136/gutjnl-2017-315852
Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res. 2021;27:2890–8.
pubmed: 33727257
doi: 10.1158/1078-0432.CCR-20-4769
McDuff SGR, Hardiman KM, Ulintz PJ, Parikh AR, Zheng H, Kim DW, et al. Circulating tumor DNA predicts pathologic and clinical outcomes following neoadjuvant chemoradiation and surgery for patients with locally advanced rectal cancer. JCO Precis Oncol. 2021;5:123–32.
Khakoo S, Carter PD, Brown G, Valeri N, Picchia S, Bali MA, et al. MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clin Cancer Res. 2020;26:183–92.
pubmed: 31852830
doi: 10.1158/1078-0432.CCR-19-1996
Murahashi S, Akiyoshi T, Sano T, Fukunaga Y, Noda T, Ueno M, et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer. 2020;123:803–10.
pubmed: 32565539
pmcid: 7462982
doi: 10.1038/s41416-020-0941-4
Wang Y, Yang L, Bao H, Fan X, Xia F, Wan J, et al. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study. PLoS Med. 2021;18:e1003741.
pubmed: 34464382
pmcid: 8407540
doi: 10.1371/journal.pmed.1003741
Zhou J, Wang C, Lin G, Xiao Y, Jia W, Xiao G, et al. Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study. Clin Cancer Res. 2021;27:301–10.
pubmed: 33046514
doi: 10.1158/1078-0432.CCR-20-2299
Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, et al. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov. 2018;8:164–73.
pubmed: 29196463
doi: 10.1158/2159-8290.CD-17-1009
Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5.
pubmed: 24658074
doi: 10.1038/nm.3511
Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27:1899–903.
pubmed: 34764486
pmcid: 8604726
doi: 10.1038/s41591-021-01553-w
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al. 386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). Ann Oncol. 2021;32:S532.
doi: 10.1016/j.annonc.2021.08.908
Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25:738–43.
pubmed: 31011204
doi: 10.1038/s41591-019-0380-z
Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, et al. Parallel evaluation of circulating tumor DNA and circulating tumor cells in metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17:80–3.
pubmed: 29195807
doi: 10.1016/j.clcc.2017.10.017
Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA, Terstappen LWMM, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:125–32.
pubmed: 16945168
doi: 10.3816/CCC.2006.n.029
Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès J-P, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013;59:1384–92.
pubmed: 23695297
doi: 10.1373/clinchem.2013.202846
Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53.
pubmed: 30616224
doi: 10.1016/j.ctrv.2018.12.006
Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5:343–50.
Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7:1529–35.
Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Fenocchio E, et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. J Clin Oncol. 2021;39:3506. https://meetinglibrary.asco.org/record/195971/abstract .
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.
pubmed: 23177514
doi: 10.1016/S0140-6736(12)61900-X
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–19.
pubmed: 25970050
doi: 10.1056/NEJMoa1414325
Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30:243–9.
pubmed: 30462160
doi: 10.1093/annonc/mdy509
Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1:276–90.
pubmed: 35122035
doi: 10.1038/s43018-020-0043-5
Passaro A, Stenzinger A, Peters S. Tumor mutational burden as a pan-cancer biomarker for immunotherapy: the limits and potential for convergence. Cancer Cell. 2020;38:624–5.
pubmed: 33171127
doi: 10.1016/j.ccell.2020.10.019
Sha D, Jin Z, Budzcies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden (TMB) as a predictive biomarker in solid tumors. Cancer Discov. 2020;10:1808–25.
pubmed: 33139244
pmcid: 7710563
doi: 10.1158/2159-8290.CD-20-0522
Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, et al. Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers. Cancers (Basel). 2021;13:2638.
pubmed: 34072037
pmcid: 8199207
doi: 10.3390/cancers13112638
Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, et al. Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy. Oncologist. 2019;24:1340–7.
pubmed: 31040255
pmcid: 6795150
doi: 10.1634/theoncologist.2019-0034
Rousseau B, Foote MB, Maron SB, Diplas BH, Lu S, Argilés G, et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med. 2021;384:1168–70.
pubmed: 33761214
pmcid: 8403269
doi: 10.1056/NEJMc2031965
Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30:1096–103.
pubmed: 31038663
doi: 10.1093/annonc/mdz134
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441–8.
pubmed: 30082870
doi: 10.1038/s41591-018-0134-3
Pich O, Muiños F, Lolkema MP, Steeghs N, Gonzalez-Perez A, Lopez-Bigas N. The mutational footprints of cancer therapies. Nat Genet. 2019;51:1732–40.
pubmed: 31740835
pmcid: 6887544
doi: 10.1038/s41588-019-0525-5
Stenzinger A, Allen JD, Maas J, Stewart MD, Merino DM, Wempe MM, et al. Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer. 2019;58:578–88.
pubmed: 30664300
pmcid: 6618007
doi: 10.1002/gcc.22733
He W-Z, Hu W-M, Wang F, Rong Y-M, Yang L, Xie Q-K, et al. Comparison of mismatch repair status between primary and matched metastatic sites in patients with colorectal cancer. J Natl Compr Canc Netw. 2019;17:1174–83.
pubmed: 31590148
doi: 10.6004/jnccn.2019.7308
Rodriguez-Casanova A, Costa-Fraga N, Bao-Caamano A, López-López R, Muinelo-Romay L, Diaz-Lagares A. Epigenetic landscape of liquid biopsy in colorectal cancer. Front Cell Dev Biol. 2021;9:37.
doi: 10.3389/fcell.2021.622459
Woolston A, Barber LJ, Griffiths B, Pich O, Lopez-Bigas N, Matthews N, et al. Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. Nat Ecol Evol. 2021;5:1024–32.
pubmed: 34017094
pmcid: 7611134
doi: 10.1038/s41559-021-01470-8
Downing A, Morris EJ, Corrigan N, Sebag-Montefiore D, Finan PJ, Thomas JD, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut. 2017;66:89–96.
pubmed: 27797935
doi: 10.1136/gutjnl-2015-311308
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312.
pubmed: 33473219
doi: 10.1038/s41571-020-00457-x
Vacante M, Ciuni R, Basile F, Biondi A. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines. 2020;8:308.
pmcid: 7555636
doi: 10.3390/biomedicines8090308
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48.
pubmed: 28252003
doi: 10.1038/nrclinonc.2017.14
Antoniotti C, Pietrantonio F, Corallo S, De Braud F, Falcone A, Cremolini C. Circulating tumor DNA analysis in colorectal cancer: from dream to reality. JCO Precis Oncol. 2019;3:1–14.
Vitiello PP, De Falco V, Giunta EF, Ciardiello D, Cardone C, Vitale P, et al. Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): a single institution experience. Cancers (Basel). 2019;11:1504.
Wan JCM, Heider K, Gale D, Murphy S, Fisher E, Mouliere F, et al. ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Transl Med. 2020;12:eaaz8084.
pubmed: 32554709
doi: 10.1126/scitranslmed.aaz8084
Massihnia D, Pizzutilo EG, Amatu A, Tosi F, Ghezzi S, Bencardino K, et al. Liquid biopsy for rectal cancer: a systematic review. Cancer Treat Rev. 2019;79:101893.
pubmed: 31499407
doi: 10.1016/j.ctrv.2019.101893
Sefrioui D, Beaussire L, Gillibert A, Blanchard F, Toure E, Bazille C, et al. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). Br J Cancer. 2021;125:725–33.
pubmed: 34112948
pmcid: 8405627
doi: 10.1038/s41416-021-01431-9
Ou S-HI, Nagasaka M, Zhu VW. Liquid biopsy to identify actionable genomic alterations. Am Soc Clin Oncol Educ Book. 2018;38:978–97.
pubmed: 30231331
pmcid: 6865813
doi: 10.1200/EDBK_199765
Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, et al. Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39:3554.
doi: 10.1200/JCO.2021.39.15_suppl.3554
Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017;28:1294–301.
pubmed: 28368441
pmcid: 5834108
doi: 10.1093/annonc/mdx112
Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28:1325–32.
pubmed: 28419195
pmcid: 5834035
doi: 10.1093/annonc/mdx125
Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018;29:1211–9.
pubmed: 29438522
doi: 10.1093/annonc/mdy061
Méhes G. Liquid biopsy for predictive mutational profiling of solid cancer: the pathologist’s perspective. J Biotechnol. 2019;297:66–70.
pubmed: 30953676
doi: 10.1016/j.jbiotec.2019.04.002
Chan HT, Chin YM, Nakamura Y, Low S-K. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers. 2020;12:2277.
pmcid: 7463455
doi: 10.3390/cancers12082277
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes [Internet]. Massachusetts Medical Society; 2014. http://www.nejm.org/doi/10.1056/NEJMoa1408617
Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol. 2018;4:1589–93.
pubmed: 29872864
pmcid: 6224316
doi: 10.1001/jamaoncol.2018.2297
Huang F, Yang Y, Chen X, Jiang H, Wang H, Shen M, et al. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer. Clin Biochem. 2021;92:46–53.
pubmed: 33737000
doi: 10.1016/j.clinbiochem.2021.03.005
Chan HT, Nagayama S, Chin YM, Otaki M, Hayashi R, Kiyotani K, et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol Oncol. 2020;14:1719–30.
pubmed: 32449983
pmcid: 7400786
doi: 10.1002/1878-0261.12727
Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol. 2017;28:784–90.
pubmed: 28104619
doi: 10.1093/annonc/mdx017